Evaluating the Effectiveness of a Chronic Disease Management Program for Gout
The aim of this study is to test the effectiveness of a pharmacist-staffed, protocol-based chronic disease management program compared to patients receiving usual care in achieving a target serum uric acid level in patients with recurrent gout.
Recurrent or Tophaceous Gout
Other: Gout Disease Management Program
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Evaluating the Effectiveness of a Chronic Disease Management Program for Gout|
- Serum Uric Acid Level [ Time Frame: change from baseline at 6 months follow up ] [ Designated as safety issue: No ]attainment and maintenance of a serum uric acid level of 6.0 mg/dl or less. The outcome will be considered positive if that level is attained and the 6 month follow up value remains at the target level.
- Serum Creatinine [ Time Frame: 0, 12, and 26 weeks ] [ Designated as safety issue: No ]Change in Serum Creatinine
- Serum Alanine Aminotransferase (ALT) [ Time Frame: 0, 12, and 26 weeks ] [ Designated as safety issue: No ]Change in serum ALT (a measure of potential toxicity)
- Gout flares [ Time Frame: 0, 12, and 26 weeks ] [ Designated as safety issue: No ]Number of gout flares
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
|Experimental: Gout Chronic Disease Management Program||
Other: Gout Disease Management Program
The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
|Active Comparator: Usual Care||
The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
Gout is a chronic condition with intermittent symptoms and should be managed through an outcome-based disease management approach. Unlike other common chronic conditions, strategies for population management in gout patients have not been tested. The study will identify adult members of Kaiser Permanente (KP) Northern California with a diagnosis of gout and 3 or more outpatient or Emergency Department visits for gout over a 1-year period preceding study enrollment. These patients will be randomized to either an active management group, or to usual care. The participants will be enrolled and followed over a period of 26 weeks. The primary outcome to be measured will be the attainment and maintenance of a uric acid lowering regimen targeted to achieve serum uric acid level of 6.0 mg/dl or less. The treatment protocol will use standard treatment guidelines to lower and maintain uric acid levels to less than or equal to 6.0 mg/dl (or maximum doses of uric acid lowering medications) and provide patient education and dietary counseling. Monitoring and medication management will be carried out by a licensed clinical pharmacist under the supervision of an experienced rheumatologist. Control subjects will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling, but otherwise receive usual care. The demonstration that a chronic disease management approach to gout care can improve the health and reduce morbidity in patients with gout may illuminate a simple path towards improved quality of life and reduced morbidity in this growing population of patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01568879
|United States, California|
|Kaiser Permanente Northern California Medical Facilities|
|All KPNC Facilities, California, United States|
|Principal Investigator:||Robert Goldfien, MD||Kaiser Permanente Northern California|